在HPV阳性口腔癌中与年龄相关的风险分层:对治疗减强的影响
Chuanhao Zhang1,2,3, Zhichao Cheng2, Xin Jiang4
1Graduate School of Dalian Medical University, Dalian, People's Republic of China.
Head & neck
|January 12, 2026
概括
一个新的HPV阳性口腔癌 (OPC) 风险分层模型将62岁确定为关键年龄门. 较年轻的患者 (<62岁) 的生存率有所改善,这表明极低风险组的治疗可能需要减缓.
科学领域:
- 在瘤学瘤学.
- 癌症研究 癌症研究
- 临床试验 临床试验
背景情况:
- 对HPV阳性口腔癌 (OPC) 的AJCC第八版分期系统需要改进,以实现个性化治疗.
- 目前的分期不足以在HPV阳性OPC中进行风险分层.
研究的目的:
- 确定HPV阳性OPC中风险分层的最佳年龄门.
- 评估年龄与整体存活率 (OS) 的关联,以改善治疗策略.
主要方法:
- 利用SEER,UHN和NCC数据库 (2018-2021) 对HPV阳性OPC病例进行调查.
- 使用受限立方线和递归分区分析 (RPA) 来确定年龄门和分层风险.
- 使用多变量考克斯比例危险模型评估预后因素.
主要成果:
- 确定62岁为关键年龄值;年龄小于62岁的患者显著改善了OS.
- 开发了一个五组风险分层模型 (极低至极高风险),具有明显的两年OS利率.
- 极低风险患者 (62岁以下,T0-2N0-1M0) 在单独放射治疗和化疗放射治疗之间没有OS差异.
结论:
- 一种针对p16阳性OPC的新型风险分层模型整合了AJCC的阶段和年龄.
- 极低风险的患者可能不会从并发化疗中受益,这表明缓和是可行的选择.
- 这些发现支持为选择的OPC患者设计未来的降级临床试验.
更多相关视频
10:26RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
Published on: March 11, 2014
28.1K
07:43Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples
Published on: July 29, 2017
10.2K
相关概念视频
01:30Cancer Vaccines
946
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
946
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K